BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Regeneron Augments I-O Portfolio with Checkmate, Partners with SpringWorks on Multiple Myeloma

  Regeneron announced it has acquired Checkmate Pharmaceuticals and that it has entered a clinical trial collaboration with SpringWorks Therapeutics to treat multiple myeloma.

  April 19, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  BioXcel Launches OnkosXcel to Advance High-Potential Oncology Asset

  New Haven, Conn.-based BioXcel Therapeutics launched a wholly-owned subsidiary, OnkosXcel, to focus on oncology.

  April 19, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Acadia’s Star CerSci Acquisition Fails First Test in Acute Pain

  Acadia Pharmaceuticals faces a major hurdle after top-line results from its study of ACP-044 for post-surgery pain failed to meet desired outcomes.

  April 19, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, MS
• 

  Drug Development

  INmune Bio Tackles Neuroinflammation in Phase II Alzheimer’s Trial

  INmune Bio has announced that it has dosed the first patient in its Phase II clinical trial of XPro1595 for the treatment of neuroinflammation as a cause of Alzheimer’s Disease.

  April 19, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Exploring the Therapeutic Potential of Protective Genetic Variations

  Genetic varations within the human genome is littered with breadcrumbs leading right up to new therapeutic possibilities.

  April 19, 2022

   · 

  5 min read

   · 

  Kaylei Whalen
• 

  Drug Development

  J&J Cuts 2022 Sales Projections by $1 Billion

  Following first-quarter results, Johnson & Johnson is projecting almost $1 billion less in revenue for the year than the initial guidance it gave in January.

  April 19, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  FDA

  Axsome and Aytu’s Positive Day with the FDA

  Axsome Therapeutics received good news regarding its NDA for AXS-05, a treatment for depression, and Aytu BioScience received Fast Track designation for its VEDS treatment.

  April 19, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Alzamend Intends to Make Lithium Safer for Alzheimer’s, Bipolar Disorder

  The possible addition of a new lithium-based drug to the list of available therapeutics is important because many physicians are reluctant to prescribe lithium.

  April 19, 2022

   · 

  4 min read

   · 

  Gail Dutton
• 

  Business

  AstraZeneca and Daiichi Sankyo Score Priority Review in NSCLC

  AstraZeneca and Daiichi Sankyo reported that their supplemental Biologics License Application (sBLA) for Enhertu was granted Priority Review by the U.S. Food and Drug Administration.

  April 19, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Cassava Faces Renewed Speculation Over Experimental Alzheimer’s Drug

  Shares of Cassava Sciences plunged after multiple Alzheimer’s researchers raised new concerns about the company’s experimental Alzheimer’s treatment, simufilam.

  April 19, 2022

   · 

  3 min read

   · 

  Alex Keown